Yeast and Mold Counts in Dietary Supplements: What Acceptable Limits Actually Look Like by Dosage Form

Supplement brands that have been through a cGMP audit know this moment. The auditor asks for your finished-product microbial specification, you hand over the spec sheet, and then they ask: “How did you arrive at this limit?” A lot of answers come back as some version of “it’s what our contract manufacturer suggested.” That’s not necessarily wrong — experienced CMOs often apply reasonable reference points — but it isn’t a defensible answer when the follow-up question is “and what’s the scientific basis for that number?”

Yeast and mold count is one of the most commonly misunderstood specifications in supplement quality systems. Brands know they need one. They don’t always know what drives it, why it changes with dosage form, or what to do when a batch comes back outside of spec. Here’s how it actually works.

The Regulatory Gap That USP Fills

FDA’s current Good Manufacturing Practice regulations for dietary supplements — 21 CFR Part 111 — require manufacturers to establish specifications for the identity, purity, quality, and composition of every finished batch. Microbiological specifications are included. What those regulations deliberately don’t do is tell you what the acceptable yeast and mold count actually is. There’s no federal table of limits you can look up and transpose onto your spec sheet.

That’s where USP Chapter <1111>, “Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use,” fills the gap. It was written for pharmaceutical products rather than dietary supplements specifically, but it’s the most widely cited reference for establishing defensible microbial acceptance criteria in the supplement industry. FDA investigators are familiar with it. Third-party auditors expect manufacturers to know it. If you’re setting a microbial limit that isn’t traceable back to USP <1111> or another peer-reviewed reference, you’re going to have a hard time in an audit.

USP <1111> organizes products into categories, and the category assignment determines the reference limits. Results are expressed in two metrics: TAMC (Total Aerobic Microbial Count) and TYMC (Total Yeast and Mold Count). The category your product falls into is determined by its physical form and route of administration — not by the manufacturer’s preference.

TYMC Reference Limits by Dosage Form

The dosage form isn’t just a packaging decision. It determines the product’s inherent microbial risk profile, which is why the reference limits differ across categories.

Non-aqueous oral preparations — hard capsules, tablets, pressed powders, softgels — fall under Category 2 in USP <1111>. The reference criteria are:

• TAMC: ≤ 10³ CFU/g (1,000 colony-forming units per gram)
• TYMC: ≤ 10² CFU/g (100 colony-forming units per gram)
• Absence of Escherichia coli in 1 g

Those are the limits most supplement brands should be working with for a standard capsule or tablet product. A TYMC of ≤ 10² CFU/g. That’s considerably stricter than a lot of incoming finished product specs we see — particularly from brands that have borrowed criteria from cosmetic or food manufacturing contexts rather than USP pharmaceutical categories.

Aqueous oral preparations — liquid supplements, functional beverages, syrups, drinkable formulas — fall under Category 1, which is substantially more restrictive:

• TAMC: ≤ 10² CFU/mL
• TYMC: ≤ 10¹ CFU/mL (ten colony-forming units per milliliter)

The logic is straightforward: free water supports microbial growth in ways that a dry capsule powder does not. If you’re manufacturing a liquid supplement and your spec sheet lists Category 2 limits because that’s what was on your quality template, that’s a meaningful error — you’re holding your product to a standard half an order of magnitude less stringent than the category requires.

Gummy supplements sit in a middle ground that trips up formulation and QA teams alike. They’re technically classified as non-aqueous — the moisture is largely bound — but their water activity can climb high enough to support mold proliferation during shelf life. Most gummies are formulated to a water activity (aw) below 0.65, which is the threshold above which most mold species can establish growth. A well-formulated gummy at aw 0.55 should be fully compliant with Category 2 TYMC limits. One that has absorbed ambient humidity during storage or shipment and climbed to aw 0.68 is a fundamentally different risk profile. We’ve encountered gummy batches that passed TYMC testing at release and would have exceeded specification by the 90-day stability timepoint. The specification is the same; the test date matters.

Botanical crude drug preparations and raw herbal ingredients are the genuine outliers in this framework. USP <1111> explicitly acknowledges that unprocessed plant materials carry elevated inherent microbial loads from cultivation, harvest, and post-harvest handling. For herbal preparations intended for oral use, TYMC reference limits in harmonized guidance can range from ≤ 10³ to ≤ 10⁵ CFU/g, depending on how extensively the material has been processed. For largely unprocessed crude botanicals, TYMC allowances are higher still. This is why a spirulina powder, a dried mushroom blend, and an ashwagandha root extract each need to be evaluated against a raw material specification separate from the finished product specification. They’re different products under different risk categories — not interchangeable.

Botanical Ingredients Drive Most of the Failures We See

In our testing program across incoming raw materials and finished dietary supplements, botanical ingredients account for the clear majority of TYMC exceedances. This isn’t surprising to a microbiologist, but it’s something brands routinely underestimate when designing a formula.

Dried mushrooms, turmeric root, black cohosh, spirulina, and similar materials come out of the ground or the ocean. They’ve been in contact with soil microorganisms, harvested with equipment that isn’t sterile by any definition, dried under conditions that may have involved temperature variation, and shipped in packaging that encounters humidity fluctuations across climate zones. A turmeric shipment arriving at a Southern California warehouse after a monsoon-season harvest in India can carry yeast and mold loads multiple orders of magnitude above what a clean excipient powder looks like.

The blending step provides dilution but not decontamination. If a botanical is formulated at 10% of a finished blend and arrives with a TYMC of 10⁴ CFU/g, the blending math puts the finished product’s contribution from that single ingredient at roughly 10³ CFU/g — an order of magnitude above the Category 2 reference limit — before any other variables are factored in. This is why a robust supplement microbiology program tests raw materials at receipt, not just finished batches. The finished product test tells you whether a given lot ships. The raw material test tells you whether you ever had a realistic chance of getting there.

One detail worth understanding if you’re evaluating contract labs: mold enumeration takes longer than aerobic bacterial count. Using USP-aligned methods, Total Aerobic Microbial Count plates incubate for 3–5 days at 30–35°C. TYMC plates run on a separate schedule — 5–7 days at a cooler 20–25°C — because those conditions mirror where yeast and mold actually proliferate. Labs that read TYMC plates at the 3-day mark alongside their aerobic count can miss slow-growing mold colonies entirely and return a result that looks clean when it isn’t. When you’re qualifying a contract microbiology lab, ask specifically about their TYMC incubation protocol and how they handle borderline colonies that appear after day 5.

What to Do When a TYMC Result Comes Back Out of Spec

An out-of-specification result isn’t automatically a rejection decision. It’s the beginning of an investigation — and the quality of that investigation matters as much as the result itself.

Start with method suitability. USP Chapter <61> requires a method suitability demonstration (the former “growth promotion” and “inhibitory properties” testing) to confirm that the product matrix isn’t suppressing microbial recovery on the plate. Some botanical extracts — particularly those with recognized antimicrobial activity like oregano oil, berberine-containing herbs, or high-polyphenol extracts — can inhibit colony formation and produce artificially low counts. If method suitability hasn’t been established for that specific product, a failing TYMC result may partly reflect matrix interference rather than true contamination. That needs to be ruled out before any disposition decision is made.

Trace the result to raw materials. Pull the incoming COAs for every botanical ingredient in the formula. Compare the TYMC values on those COAs against what you’d expect in the finished blend using the weight percentages. If one ingredient’s incoming TYMC was already near specification, basic dilution calculations should tell you whether that material is the probable source — and whether the incoming COA should have triggered a hold before manufacturing began.

Document the investigation fully. FDA’s 21 CFR Part 111 is specific: retesting following an out-of-specification result requires a documented investigation with a root cause conclusion before any release decision is scientifically defensible. “We re-tested and it passed” without accompanying investigation documentation is a citation waiting to be written. The re-test result may be used as part of the investigation, but it doesn’t replace the investigation.

Building a Spec You Can Actually Defend

The number on your finished product specification is only as solid as the reasoning that produced it. Brands that set their TYMC at ≤ 10³ CFU/g because it was on a template, or at ≤ 500 CFU/g because their CMO mentioned it, haven’t built a quality system — they’ve borrowed one that may not fit their actual product risk profile.

Start with the USP <1111> category that matches your dosage form. Then map your formula’s botanical ingredients: what materials carry inherent microbial load, at what inclusion percentages, and what does the blending math tell you about realistic finished product counts? If your capsule product consistently achieves TYMC results in the 10–30 CFU/g range, a specification of ≤ 10² CFU/g is scientifically grounded and appropriately challenging. If your botanical-heavy powder routinely comes in at 80–90 CFU/g finished, you have a raw material sourcing or incoming testing problem — not a reason to move the specification.

A complete supplement microbiology program covers TYMC at raw material receipt, at in-process blend, and at finished product release. It uses methods that are validated or verified for suitability with each matrix. And it treats an out-of-specification result as data worth understanding rather than a number to retest until it disappears.

Getting this right doesn’t require overhauling your entire quality system. It requires knowing which USP category your product sits in, understanding what your botanical ingredients bring to the blend, and building a specification that reflects the product you’re actually making.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• Supplier Qualification and COA Verification for Raw Materials — How to assess incoming botanical and raw material documentation before a high TYMC result reaches your finished product.
• GMP Audit Preparation for Dietary Supplement Facilities — What FDA investigators look for in your microbiological specification and investigation records during a 21 CFR Part 111 inspection.
• NHP Microbiology Testing Under Health Canada’s NHPD — How Canada’s natural health product regulations approach microbial acceptance criteria — and where they diverge from the USP framework.